在2010-2020年间死后儿科人口中遇到的非处方药物
Jennifer L Swatek1, Stephanie M Marco1, Kari M Midthun1
1Toxicological Services, NMS Labs, 200 Welsh Rd, Horsham, PA 19044, USA.
儿科法医毒理学案例经常涉及常见的非处方药 (OTC) 药物. 抗胰岛素,感冒/流感药和止痛药在死后儿科病例中最常见.
科学领域:
- 法医毒理学 法医毒理学
- 儿科药理学 儿科药理学
背景情况:
- 与成年人相比,儿童群体表现出独特的毒动力学和毒动力学特征.
- 儿童,特别是五岁以下儿童的非处方药 (OTC) 的剂量考虑与成人剂量有很大差异.
- 由于发育差异,OTC药物的使用需要在儿科法医毒理学中仔细评估.
研究的目的:
- 分析涉及常见OTC药物的死后儿科病例的趋势.
- 确定在儿科死后毒理学中发现的最常见的OTC药物类别.
- 检查儿科人口中OTC药物暴露的年龄相关模式.
主要方法:
- 编制和分析了2010-2020年间的死后儿科数据.
- 确定的病例对常见的OTC药物呈阳性,包括抗胰岛素药物,止痛药,感冒/流感药物,胃肠道辅助药和睡眠辅助药.
- 将儿科病例分为三个年龄组:出生-5岁,6-11岁和12-18岁.
主要成果:
- 总共有1413个涉及常见OTC药物的阳性病例被确定.
- 抗胰岛素,感冒/流感药物和止痛药是最常见的药物类别.
- 与较年轻 (出生-5岁) 和较年长 (12-18岁) 的儿科组相比,6-11岁年龄组的病例流行率较低.
结论:
- 常见的OTC药物经常与死后儿科法医毒理学病例有关.
- 特定于年龄的毒动力学和毒动力学差异需要针对儿童毒理学的量身定制方法.
- 这些发现凸显了儿童群体中无意中过量服用,滥用和自杀性过量服用涉及OTC药物的可能性.
更多相关视频
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
13:35A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
Published on: March 1, 2018
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Factors Affecting Drug Response: Overview
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Parenteral Anesthetics: Overview
Drug Classes and Categories
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
